Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study

Authors

  • Marin Strijker Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
  • Ali Belkouz Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
  • Lydia G. van der Geest Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands
  • Thomas M. van Gulik Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
  • Jeanin E. van Hooft Department of Gastroenterology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
  • Vincent E. de Meijer Department of Surgery, University of Groningen, University Medical Center, Groningen, the Netherlands
  • Nadia Haj Mohammad Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
  • Philip R. de Reuver Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands
  • Joanne Verheij Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
  • Judith de Vos-Geelen Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands
  • Johanna W. Wilmink Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
  • Bas Groot Koerkamp Department of Surgery, Erasmus Medical Center, Rotterdam, the Netherlands
  • Heinz-Josef Klümpen Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
  • Marc G. Besselink Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

DOI:

https://doi.org/10.1080/0284186X.2019.1590634

Abstract

Background: Population-based data on distal cholangiocarcinoma (DCC) from the Western world are not available, albeit essential to identify areas for improvement. This study investigated the incidence, treatment and outcomes, including time trends and predictors for survival, in a nationwide cohort of DCC.

Methods: This is a retrospective cohort study of patients diagnosed with DCC (2009–2016) derived from the Netherlands Cancer Registry. Overall survival (OS) and its predictors were analyzed using Kaplan–Meier and Cox regression analysis. Time trends (2009–2012 versus 2013–2016) were assessed.

Results: Overall, 1338 patients with DCC were included, with 1-, 3- and 5-year OS of 46%, 18%, and 11%. Incidence of DCC was 0.55–0.90 per 100.000 per year. Median OS was 10.4 months across all stages; 21.9 months for resected (n = 620, 46.3%), 6.7 months for unresected nonmetastatic (n = 445, 33.3%), and 3.6 months for metastatic DCC (n = 273, 20.4%) (p < .001). After resection, 30-day mortality was 4.8% and 90-day mortality 7.7%. Patients with metastatic DCC who received chemotherapy (n = 78, 28.6%) had a median OS of 8.2 versus 2.8 months for those not treated (p < .001). Over time, resection rates (53.6% to 61.7%, p = .008) and use of palliative chemotherapy in metastatic DCC (22.3% to 32.9%, p = .05) increased, without improvement in OS (10.3 vs 10.6 months, p = .55). Independent poor prognostic factors for OS in resected disease were increasing age, pT3/T4 stage, higher lymph node ratio, poor differentiation, and R1 resection.

Conclusions: In a nationwide cohort of DCC, resection rates and the use of chemotherapy increased whereas OS remained stable at 10.4 months.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2019-07-03

How to Cite

Strijker, M. ., Belkouz, A. ., van der Geest, L. G. ., van Gulik, T. M. ., van Hooft, J. E. ., de Meijer, V. E. ., … Besselink, M. G. . (2019). Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncologica, 58(7), 1048–1055. https://doi.org/10.1080/0284186X.2019.1590634

Issue

Vol. 58 No. 7 (2019): Acta Oncologica

Section

Articles